Biomarqueurs pour prédire l’efficacité de l’immunothérapie dans le cancer de l’ovaire

Objectif(s) de la recherche et intérêt pour la santé publique

Finalité de l'étude

Objectifs poursuivis

Domaines médicaux investigués

Bénéfices attendus

Primary objectives:
1. Determine the impact of CD8/FoxP3 ratio defined by brightfield multiplex IHC on OS under atezolizumab, as compared to the placebo arm
2. Determine the impact of 3 additional markers by brightfield multiplex IHC (to be determined in Neopembrov and HUG cohorts) on OS under atezolizumab, as compared to the placebo arm

Secondary objectives:
1. Determine the impact of CD8/FoxP3 ratio by brightfield multiplex IHC on PFS under atezolizumab, as compared to the placebo arm
2. Determine the impact of 3 additional markers (to be determined on other HUG and Neopembrov) on PFS under atezolizumab, as compared to the placebo arm
3. Determine the prognostic value of CD8/FoxP3 ratio on OS

505 patients included in the clinical study ATALANTE « Etude randomisée, en double
aveugle, de phase III comparant l’atezolizumab à un placebo chez des patientes atteintes
d’une rechute tardive de cancer épithélial de l’ovaire, des trompes de Fallope ou du
péritoine, traitées par une chimiothérapie à base de platine et du bévacizumab » will be
analyzed.

Patient characteristics will be compared using Fisher’s exact test. The survival functions of the different subgroups will be estimated using the Kaplan–Meier method and compared using a log-rank test. The relative hazards for group will be estimated with a Cox proportional hazards model adjusted for age, PFI, BRCA status and previous bevacizumab. The categorical covariates included in the model will be PFI (6-12 vs ≥12) and BRCA status (positive vs negative).